Quick Answer
Metagenomi Therapeutics, Inc. reported Total Assets of $221.10 million for fiscal year 2025.
Metagenomi Therapeutics, Inc. Total Assets — Annual History
| Fiscal Year | Total Assets | YoY Change |
|---|---|---|
| 2025 | $221.10M | -31.9% |
| 2024 | $324.60M | -11.0% |
| 2023 | $364.84M | — |
Quarterly Total Assets
| Quarter Ending | Total Assets | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $247.94M | -30.8% | -8.9% |
| June 30, 2025 | $272.28M | -29.4% | -8.6% |
| March 31, 2025 | $297.87M | -28.3% | -8.2% |
| December 31, 2024 | $324.60M | -11.0% | -9.4% |
| September 30, 2024 | $358.35M | — | -7.1% |
| June 30, 2024 | $385.90M | — | -7.1% |
| March 31, 2024 | $415.40M | — | +13.9% |
| December 31, 2023 | $364.84M | — | — |
- Metagenomi Therapeutics, Inc. showed a decrease of -31.9% in Total Assets compared to the prior fiscal year.
- Over the 2023–2025 period, Metagenomi Therapeutics, Inc.’s total assets has declined by 39.4% (from $364.84 million to $221.10 million).
- The most recent figure is from Metagenomi Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 5, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: